Background: Clinical trials suggest that sotalol and dofetilide are much more effective in preventing atrial fibrillation (AF) than in terminating it. This study evaluated potential mechanisms of discordant sotalol and dofetilide effects on AF termination vs. prevention. Methods: We applied 240-electrode epicardial mapping and programmed stimulation in a vagotonic dog model of AF before and after dofetilide or sotalol. Results: Under control conditions, sustained AF could be induced by single S extrastimuli that caused unidirectional 2 block and macroreentry. Sotalol (2 mg / kg) and dofetilide (0.04 mg / kg) failed to terminate AF in any dog, but prevented AF induction by S stimuli in 19 / 22 (86%) and 4 / 5 (80%) of animals, respectively. With sotalol and dofetilide, unidirectional block still occurred, but 2 wavefront reentry failed. The prevention of S -induced reentry was related to large increases in the effective refractory period (ERP) at a 2 BCL of 1000 ms, leading to ERPs that exceeded the conduction delay following S . Reverse use-dependent effects resulted in smaller 2 ERP increases at BCLs closer to the AF cycle length. Although the number of zones of reactivation per cycle during sustained AF were decreased by sotalol and dofetilide, the changes were small and insufficient to terminate AF. Conclusions: Sotalol and dofetilide prevent AF initiation by premature depolarizations at doses that fail to terminate vagotonic AF, by increasing ERP at the basic cycle length beyond the associated conduction delay that leads to reentry.
Introduction
drugs to be relatively ineffective in terminating AF, but effective in preventing AF recurrence [5] . Experimental Atrial fibrillation (AF) is the most common sustained studies in vagotonic and atrial tachycardia-related models arrhythmia in clinical practice and causes a wide range of of sustained AF have demonstrated a limited capacity of potential complications [1] . The treatment of AF remains clinically-relevant doses of rapid delayed rectifier (I )-Kr problematic [2] . A better understanding of the mechanisms selective blocking class III agents to terminate AF [6] [7] [8] . determining antiarrhythmic drug efficacy would help in
In a previous report from our laboratory, we suggested that improving therapy. With the awareness of the risks of reverse use-dependent actions may limit class III efficacy potent class I antiarrhythmic drugs obtained from the at the rapid rates of AF, but permit them to prevent AF Cardiac Arrhythmia Suppression Trial [3] and subsequent induction by atrial premature complexes (APCs) at slower analyses [2] , antiarrhythmic drug development shifted to resting sinus rates [6] . This concept has never been tested class III agents [4] . Clinical trials have shown class III experimentally. We therefore designed the present study to (1) determine whether sotalol and dofetilide doses that are ineffective in terminating AF are capable of preventing AF induction by APCs and (2) use epicardial mapping to 2.3. Measurement of electrophysiological variables evaluate the mechanism by which AF induction is prevented.
Activation maps for CV measurements were obtained after 45 s of pacing at the right atrial appendage at basic cycle lengths (BCLs) of 200, 300, 400 and (whenever possible)1000 ms. Fifteen basic (S ) stimuli were followed 
Methods
by a premature (S ) stimulus at an S S interval that was 2 1 2 reduced by 10-ms decrements from the BCL, with the ERP 2.1. General preparation defined as the longest S S interval failing to produce a 1 2 response. AF was then induced with single S s at a BCL of 2 The investigation conforms with the Guide for the Care 1000 ms (or the longest cycle length maintaining 1:1 system. interval. The heart was exposed via a sternotomy and a pericar-
The AFCL was calculated at each of 50 widely-distribdial cradle created. A programmable stimulator (Digital uted sites by counting cycles over a 2-s activation window. Cardiovascular Instruments, Berkeley, CA) was used to
The results at all sites were averaged to obtain the overall stimulate the right atrium with 2-ms, twice diastolic-thresmean AFCL. The activation pattern during AF was studied hold pulses. A ventricular demand pacemaker was used to by constructing sequential activation maps. Zones of stimulate the ventricles at 80 / min when the ventricular rate reactivation were defined as discrete areas of early activabecame excessively slow. The vagus nerves were isolated tion adjacent to zones of late activation in a cycle, that and divided in the neck. To block cardiac b-adrenergic were reactivated at the onset of the next cycle. The number effects, nadolol was administered at 0.5 mg / kg i.v., of reactivation zones was determined for three successive followed by 0.25 mg / kg i.v. every 2 h. The sinus node was AF cycles in each dog under each condition. crushed to permit atrial capture at cycle lengths compar-CV was determined by analyzing activation during able to resting cycle lengths (800-1000 ms) in man.
continuous longitudinal propagation at five electrode sites in Bachmann's bundle (Fig. 1) . Distance from the proxim-2.2. AF model al site was plotted against activation time, and CV was determined from the slope of the best-fit regression line Experiments were performed in a well-characterized (Fig. 1C) . The same sites were used for all conduction model of vagotonic AF [6, 7] . This model was chosen over velocity measurements for each experiment. The wavethe atrial-tachycardia model [8, 9] because repeated induclength was calculated as CV3ERP. tions of AF were needed to characterize susceptibility to AF induction by APCs. Repeated episodes of sustained AF 2.4. Activation mapping would require repeated electrical cardioversions in the atrial-tachycardia model. Sustained vagotonic AF can be Five silicon plaques containing 240 bipolar electrodes terminated by stopping vagal stimulation, without requirwere attached to the epicardial surface of both atria [8, 10] . ing electrical cardioversion, and permitting the subsequent Electrodes consisted of Teflon-coated stainless steel wires resumption of vagotonic conditions by re-instituting vagal (270 mm diameter) with interpolar distances of 1 mm, stimulation during sinus rhythm.
inter-electrode distances 3-6 mm. A decapolar ring-elecBipolar hook electrodes (stainless steel insulated with trode catheter (10 electrodes, 2.5 mm inter-polar and 10 Teflon except for the distal 1-2 cm) were inserted within mm inter-electrode distance) was inserted via the femoral and parallel to each vagus nerve. Bipolar stimulation (0.1-vein and positioned fluoroscopically adjacent to the septum ms square-wave pulses, 10 Hz, 60% of voltage for to record five bipolar septal electrograms. Electrogram asystole) was applied (Grass DS-9F stimulator) continusignals were filtered (10-450 Hz), digitized (12-bit resously during AF, the measurement of ERP and conduction olution and 1-kHz sampling rate), and transmitted into a velocity (CV), and AF induction.
Silicon Graphics computer. Activation times were ana-prepared on the day of each experiment and (for dofetilide) protected from light. Vagal stimulation parameters were defined as described above, and maintenance of AF during 20 min of vagal stimulation under control conditions was verified. AF was then re-initiated and maintained for 20 min, to confirm AF stability. AF was then terminated and AERP and CV were measured at four BCLs (200, 300, 400 and 1000 ms) during vagal stimulation. If AF was induced by single S s at a BCL of 1000 ms, an activation window 2 was obtained for subsequent mapping and AF was terminated. Following a 5-min rest period, vagal stimulation was re-initiated and AF induction re-tested at the same coupling interval. The window of vulnerability was defined as the range of coupling intervals over which AF was consistently induced by single extrastimuli. AF was then re-induced during vagal stimulation, and a drug given after 5 min of AF. If AF was not stopped 20 min after drug administration, activation data were obtained and vagal stimulation was discontinued to return to sinus rhythm. Electrophysiologic measurements were then repeated during vagal stimulation, and induction of AF attempted. If sustained AF could not be induced, an S was 3 introduced at the shortest S -S interval maintaining 1 2 capture to define the ERP of the APC initiated by S , 2 activation data were obtained and the experiment was terminated.
Statistical analysis
Data are expressed as mean6S.E. Statistical comparisons were made with ANOVA followed a range test (Bonferroni-adjusted t for two-way ANOVA and Tukey's test for one-way ANOVA). drugs significantly prolonged atrial ERP, with changes lyzed off-line with computer-determined peak-amplitude increasing with increasing BCL (reverse use-dependence, criteria. All computer-selected events were verified manu- Fig. 3 ). Changes in wavelength also showed reverse useally.
dependence (Fig. 4) .
Experimental protocol 3.2. Effects on AF
The effects of sotalol (loading dose of 2 mg / kg followed by infusion of 1 mg / kg / h) and dofetilide (loading Neither sotalol nor dofetilide terminated AF in any dog, dose 0.04 mg / kg, infusion 0.008 mg / kg / h) were studied. but both drugs prevented AF induction by single extrasThe doses were established by preliminary experiments to timuli. Under control conditions, single extrastimuli inproduce significant and constant atrial ERP prolongation duced sustained AF in all dogs, with a vulnerable window without terminating AF in most dogs. All drugs were from 9765 to 11167 ms in the sotalol group and 8364 to administered via infusion pump, with drug solutions 9668 ms in the dofetilide group. Sotalol prevented AF induction by extrastimuli in 19 / 22 dogs (86%) and delay is greater than the ERP at the stimulation site, dofetilide prevented AF induction in 4 / 5 dogs (80%).
permitting reactivation in the right atrial appendage and To understand the mechanisms by which sotalol and resulting in the unstimulated reentrant activation (B3) at dofetilide prevented AF induction, we analyzed activation the right. maps during AF induction under control conditions and Fig. 5B shows the results of programmed stimulation at then after drug during application of the most closelythe same site in the same dog after sotalol administration. coupled extrastimuli with capture. the AV ring, and across Bachmann's bundle to the left was 106 ms and no reentry followed. The right panel atrium. The upper end of the septum is activated at 71 ms, shows activation resulting from the earliest complex that and the lower end of the septum is activated with a could be initiated by an S at the same stimulation site, 3 conduction delay (defined as conduction time from initial with an S -S interval of 140 ms, which also failed to 2 3 activation near the stimulation site to activation of the induce reentry. The ERP of the complex resulting from S 2 distal septum) of 97 ms. The ERP of the complex resulting was thus 130 ms, longer than the septal conduction delay from S was 100 ms, and an S was applied 110 ms after and potentially accounting for the failure of reentry from RA appendage. The lack of reentry with S must then be 3 due to block at a site in the reentrant pathway with an ERP longer than the ERP at the RA appendage, or to reentry data from dogs in which sotalol and dofetilide prevented actually involving a region more proximal in the septum AF induction by single electrically-induced APCs. Under than the distal recording site.
control conditions, the conduction delay to the distal Fig. 6A shows the induction of reentry under control septum slightly exceeded the ERP of the activation caused conditions in a dog from the dofetilide group. The septal by S , permitting reentry. Both dofetilide and sotalol 1 conduction delay resulting from the earliest S with capture substantially increased the ERP, so that it exceeded the 2 (middle panel) was 101 ms (of the same order as the basic distal septal conduction delay and reentry was prevented. ERP at the right atrial appendage), activating the distal Fig. 8A shows consecutive cycles (defined as the septum at 228 ms. This delay was sufficient to activate the shortest interval with activation at all sites) during AF right atrial free wall 24 ms later (at 252 ms), resulting in before and after sotalol. Zones of reactivation are indicated the reentrant response shown at the right. Fig. 6B shows by the stars. Sotalol decreased slightly the number of zones failure of reentry for the earliest-coupled S and S with of reactivation and prolonged the cycle length, consistent 2 3 capture in the presence of dofetilide. Once again, the septal with an increase in the ERP; however, multiple reactivaconduction delay associated with S was substantially less tion zones are present both before and after the drug. Fig.   2 than the ERP of the activation caused by S (140 ms), 8B shows the same type of data for a dog in the dofetilide 2 accounting for the failure of reentry from the septum to the group, illustrating qualitatively similar phenomena to those right atrium. seen with sotalol. Fig. 9 shows a quantitative analysis of Under control conditions, premature stimulation at the the AFCL (panel A) and number of reactivation zones right atrial appendage generally appeared to cause reactiva-(panel B) before and after each drug. Both drugs increased tion of the right atrium via the septum. Fig. 7 shows mean AFCL and decreased the number of reactivation zones per from stimulation site to distal septum; ERP5effective refractory period at stimulation site. Arrows indicate direction of wavefront propagation. Double line is site of failure of reentry, presumably due to persistent right atrial refractoriness. Isochrone lines (20-ms isochrones) were generated automatically by a validated computer algorithm. Note that septal activation times (shown in boxes) were out of the epicardial plane and were intentionally excluded from epicardial isochrone calculation.
cycle; however, the decrease in the number of reactivation 4.1. Efficacy of class III drugs in preventing AF zones was relatively modest, from just above six to just compared to their ability to terminate the arrhythmia above five.
Numerous studies attest to the greater efficacy of class III drugs, and more specifically sotalol and dofetilide, in preventing AF compared to their ability to terminate the 4. Discussion arrhythmia. In a controlled trial, Hohnloser et al. [5] found that sotalol converted significantly fewer AF patients than In the present study, clinical doses of sotalol and quinidine to sinus rhythm, but that their efficacy in AF dofetilide failed to convert sustained AF in a vagotonic prevention is equivalent. Two other studies found sotalol dog model. Nonetheless, the same doses were highly to be inferior to quinidine for AF cardioversion [11, 12] , effective in preventing AF initiation by electrically induced and an additional study found sotalol to be significantly atrial premature beats. The mechanism by which the less effective than flecainide [13] . In contrast, sotalol has initiation of intra-atrial reentry was prevented appeared to been found to be as effective as quinidine [14, 15] and be a strong increase in the ERP at long basic cycle lengths, propafenone [16, 17] and more effective than placebo [18] which exceeded the conduction delay associated with in preventing AF recurrence. premature activation.
Two small studies failed to demonstrate efficacy of dofetilide in AF conversion [19, 20] . Subsequent larger the failure of sotalol and dofetilide to terminate AF, in that studies showed that dofetilide is more effective than despite increasing the AFCL these drugs failed to reduce placebo in terminating AF and atrial flutter; however, the number of reactivation zones per AF cycle in any dofetilide conversion rates for AF are relatively low: important way. Allessie et al. [24] have previously shown 14.5% in one study [21] and 24% in the other [22] . In that vagal AF is maintained by an average of four to six contrast, dofetilide is clearly effective in preventing AF functional reentry wavefronts. Although both dofetilide recurrence [23] . Thus, the clinical evidence suggests that and sotalol reduced the number of reactivation zones sotalol and dofetilide are more effective in preventing AF during AF significantly, the number of such zones dethan in terminating it.
creased from just over six to just over five per cycle, an effect insufficient to terminate AF. The differential efficacy 4.2. Novel findings and relationship to previous of these agents in AF prevention vs. termination is literature therefore likely related to their reverse use-dependent actions on ERP, such that ERP is more prolonged at slower Our study is the first of which we are aware to rates like those of sinus rhythm than during AF. This demonstrate, in an experimental model of AF, differential possibility was suggested by an earlier study in our efficacy of class III drugs for AF termination vs. prevenlaboratory [6] , but has never before been tested experimention that parallels clinical observations. In addition, we tally. gained insights into the mechanism by which these drugs Previous studies have shown that clinically relevant prevented AF initiation by APCs with the use of epicardial doses of sotalol [6, 25] and dofetilide [8] are relatively mapping. Efficacy in preventing AF initiation was associineffective in terminating vagotonic AF. Our finding of an ated with substantial ERP prolongation at rates comparable important role of the septum in AF initiation are compatto sinus rhythm in man, such that the ERP exceeded the ible with previous observations in the sterile pericarditis conduction delay that produced reentry under control model [26] . In contrast to our findings, Wijffels et al.
[27] conditions. Epicardial mapping also provided insights into reported that a variety of antiarrhythmic drugs (hydro- having to resort to electrical cardioversion. This is an quinidine, cibenzoline, flecainide and d-sotalol) terminate important advantage for a study evaluating vulnerability to chronic AF in goats with tachycardia-induced remodeling, AF initiation by premature atrial extrastimuli in a milieu but do not prevent the reinitiation of AF. Reasons for the that supports sustained AF, because AF is induced rediscrepancy are not clear, but could be related to different peatedly over the course of the study. A requirement for species (dog vs. goat), models (vagotonic vs. tachycardiarepeated electrical cardioversion would introduce a subremodeling AF), or methods of drug infusion (loading and stantial additional variable to the study (electrophysiologimaintenance vs. single infusion rate causing progressive cal effects of repeated cardioversion), and the waiting increases in drug concentration). In the Wijffels study, times necessary for restabilization after each cardioversion d-sotalol did not appear to alter atrial ERP, which could would greatly lengthen the study, decreasing feasibility explain the failure to prevent AF initiation, but still leaves and increasing the risk of systematic time-dependent the ability to terminate AF unexplained. One clinical study changes. Although enhanced vagal tone may be important has demonstrated efficacy for sotalol in preventing early in many clinical cases of AF [29] , a prominent role of re-initiation of AF by APCs following internal cardiovervagal tone is not observed in the majority of cases. sion of the arrhythmia [28] .
Nonetheless, the responses of vagotonic AF to antiarrhythmic drugs resemble those for chemical cardioversion of 4.3. Limitations recent-onset clinical AF [30] , and some of the primary electrophysiological features of vagotonic AF (decreased The model we used was vagotonic AF. We chose this ERP, decreased ERP rate-adaptation and increased ERP model primarily because sustained AF can readily be heterogeneity) resemble those observed in tachycardiaterminated by stopping vagal nerve stimulation, without induced atrial remodeling [9, 31] . The lack of sotalol useful drug as a primary agent [32, 33] or accessory compound [35] in the termination of AF. Ibutilide has been shown superior in AF termination compared to sotalol [33] and procainamide [34] . This discrepancy may be due to an additional mechanism of ibutilide's class III action (en-1 hancement of a plateau Na current) [36] in addition to I Kr blockade [37] . The limitations of our mapping methods also need to be kept in mind. It appeared in many cases that reactivation involved the atrial septum and was directed towards the region of the initiating extrastimulus. However, endocardial activation (other than at the septum) is not accessed by the epicardial electrode arrays we used, and the resolution of all mapping systems is limited. Consequently, a degree of uncertainty remains regarding the precise pathways of reactivation and the underlying determinants.
Finally, we cannot completely exclude an interaction between sotalol and vagal effects. Sotalol has been shown to inhibit cholinesterase activity [38] , and to reduce I K.Ach [39] . However, these actions are seen at concentrations (.300 and 100 mM, respectively) that are .6-fold the average concentrations (|15 mM) achieved by the doses used in the present study [6] . Furthermore, in previous studies we have shown that neither sotalol nor dofetilide at the doses we used alter the vagal frequency-heart rate change relationship [6, 7] . 
Conclusions
efficacy observed in the present study has also been We found that sotalol and dofetilide are more effective reported in patients with vagal AF [32] . Nonetheless, it in preventing AF initiation by APCs than in terminating should be recognized that the arrhythmic substrate in vagal sustained AF in a vagotonic model. The efficacy in AF likely differs from other animal models and from the preventing AF induction appeared to be due to strong substrate in chronic AF in man.
increases in the AERP at slow rates, such that the The second important point is that although the present maximum conduction delay was insufficient to allow for study obtained results with class III drugs very similar to reentry. At the rapid rates of AF, alterations in atrial those observed clinically (more efficacy in AF prevention reactivation were relatively small, presumably because of than termination), we do not wish to imply that the reverse use-dependent effects on ERP, and insufficient to mechanisms responsible for differential efficacy in the terminate AF. These results provide potential insights into present study are the only factors underlying the clinical the mechanisms by which sotalol and dofetilide prevent observations. For example, sustained AF causes atrial AF occurrence more effectively than they terminate the remodeling. We have observed much lower efficacy of arrhythmia. dofetilide in terminating AF in dogs with atrial tachycardia-induced remodeling than in dogs with AF sustained in a heart failure substrate [8] . Thus, some of the
